Nanoparticle Solution Manufacturing via Ultrasonic Homogenization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for manufacturing nanoparticles of acetylsalicylic acid, diosmin, or drotaverine do not effectively enhance their bioavailability and stability, leading to potential aggregation and reduced efficacy.
Innovation Solution
Dissolving acetylsalicylic acid or diosmin or drotaverine in an organic solvent, mixing with dispersing agents in water, and using ultrasonic homogenization to create nanoparticles with diameters between 50-500 nm, stabilized by lecithin, gelatin, and starch, preventing aggregation and enhancing bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nanoparticle manufacturing methods are used, then nanoparticle formation is achieved, but bioavailability and stability are not effectively enhanced
Solution Approach 1:
The patent changes the physical-chemical parameters of the system by using ultrasonic homogenization to transform macroscopic particles into nanoparticles (50-500 nm size range). This parameter change in particle size directly enhances bioavailability and stability while maintaining manufacturing feasibility through a relatively simple process
Solution Approach 2:
The patent applies ultrasonic vibration (mechanical vibration) to homogenize the mixture of organic and aqueous phases, breaking down particles into nanoscale dimensions. This mechanical energy input achieves stable nanoparticle formation with improved bioavailability without complex manufacturing steps
2Reliability
If nanoparticle aggregation occurs, then particle size increases, but stability and bioavailability are reduced
Solution Approach 1:
The patent introduces an intermediary substance (surfactant or stabilizer) that mediates between the hydrophobic nanoparticle core and the aqueous environment. This intermediary prevents aggregation by providing steric or electrostatic repulsion, maintaining stable particle size distribution and enhancing overall stability
Solution Approach 2:
The patent forms a protective shell or film around the nanoparticle core using polymers or surfactants. This flexible coating prevents particle aggregation while maintaining the integrity and size of the nanoparticles, ensuring stable composition and improved bioavailability
3Quantity of substance
If organic solvent concentration is increased to dissolve active substance, then solubility improves, but toxicity and stability may worsen
Solution Approach 1:
The patent replaces chemical dissolution mechanisms with physical homogenization through ultrasonic treatment. Instead of relying on high concentrations of organic solvents to dissolve the active substance, the process uses mechanical energy to disperse particles at the nanoscale, reducing the need for toxic solvents while maintaining solubility and stability
Solution Approach 2:
The patent utilizes phase transition principles by creating a biphasic system (organic and aqueous phases) that transitions into a stable nanoparticle dispersion. The active substance partitions between phases during homogenization, achieving high solubility in the final nanoparticle form without requiring excessive organic solvent, thus reducing toxicity while maintaining stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces stable, bioavailable nanoparticle solutions that maintain particle size and stability, ensuring effective administration and manufacturing of medicinal products with improved efficacy.
Implementation Method 1
the obtained mixture is homogenised through the use of ultrasonic frequencies until homogenous solution is obtained
Implementation Method 2
the obtained mixture is homogenised through the use of ultrasonic frequencies
Implementation Method 3
at least one dispersing agents is dissolved in water... stabilized by lecithin, gelatin, and starch
Implementation Method 4
at least one dispersing agents is dissolved in water... The solution possesses enhanced bioavailability and is very stable as the nanoparticles do not aggregate
Data Source
AI summary
A method of manufacturing a solution of acetylsalicylic acid or diosmin or drotaverine nanoparticles, where a acetylsalicylic acid or diosmin or drotaverine is dissolved in an organic solvent, and at least one dispersing agents is dissolved in water, then the organic solution is added to the aqueous solution and the obtained mixture is homogenised until homogenous solution is obtained. Preferably the organic solvent is ethanol or DMSO and the dispersing agent is gelatine, starch and/or lecithin.